Biohaven Pharma

BHVN NYSE
43.77
-0.34
-0.76%
Opening 10:24 07/22 EDT
Open
43.64
Prev Close
44.10
High
44.40
Low
42.72
Volume
261.70K
Avg Vol (3M)
995.45K
52 Week High
67.86
52 Week Low
29.17
% Turnover
0.51%
Market Cap
2.27B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Biohaven Pharma BHVN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
MORE >

Recently

Name
Price
%Change